Targeted Nutritional Supplement After Lumbar Spine Surgery: A Randomized, Placebo-Controlled, Double-Blind Trial
Key facts
- Who runs it
- University of California, Irvine
- Where
- Orange, United StatesSee the site
- Trial code
- Status
- Withdrawn
- Started
- Jan 2025
- Ended
- Jul 2026
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Essential amino acids
- Alanine
- Record updated
- 29 May 2025
- Why it stopped
- Institutional barriers.
Who can take part
- Age
- 18 years to 80 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (30)Hide the full registry criteria
Who can take part
- Diagnosis of lumbar pathology requiring lumbar spine surgery without previous surgical intervention
- Failure of more conservative treatment options
- If undergoing fusion, surgery consists of short segment fusion of less than or equal to 5 levels without staged surgery
- Provided voluntary written informed consent to participate in the study
- Able to comply with all study procedures, including taking the assigned treatment or placebo as instructed and attending follow-up visits
- No restrictions on the use of nutritional supplements or dietary modifications
- Able to complete self-report questionnaires and assessments as required by the study protocol
- Confirmed ambulatory status prior to surgery
Who cannot take part
- Diagnosis other than lumbar spine pathology requiring lumbar spine surgery
- Prior protein-calorie supplementation for other clinical indications
- Recent treatment with anabolic steroids or oral corticosteroids for >1 week
- Uncontrolled endocrine disease; heart, kidney, liver, blood, or respiratory disease; peripheral vascular disease
- History of congenital metabolic disease (e.g Hartnup disease, Phenylketonuria)
- Active cancer
- Active infection
- History of chronic opioid consumption > 6 months
- History of major head trauma
- History of dementia
- Specific dietary restrictions or allergies that prevent the use of nutritional supplements or dietary modifications
- Comorbidities excluding the use of the proposed nutritional supplement or resulting in decreased serum albumin levels (phenylketonuria, galactosemia, nephrotic syndrome)
- HbA1c > 7.0
- Non-ambulatory status
- Unable or unwilling to comply with study procedures, including taking the assigned treatment or placebo as instructed and attending follow-up visits
- Testosterone or Androgen Supplementation
- Pregnant/breastfeeding women
- Vulnerable populations (minors, prisoners)
- Lack of decision making capacity
- BMI <18 or > 40
- Patients with pacemakers
- Currently enrolled in another clinical trial involving interventions that may interfere with the outcomes of this study
Where in United States
- University of California Irvine Medical CenterOrange, United States
About the trial
What the trial wants to find out
The goal of this clinical trial is to prospectively evaluate the effects of essential amino acid (EAA) supplementation on the volume and structure of the muscles surrounding the spine (paraspinal musculature). The main questions it aims to answer are:
Read full original descriptionShow less
* Does EAA supplementation preserve paraspinal muscle volume (PMV) and influence changes to spinal alignment following lumbar spine surgery? * Does preserving paraspinal muscle volume (PMV) improve post-operative functional status? * Does preserving PMV reduce post-operative complications, pain, and opioid consumption?
Participants will be asked to:
* Consume either EAA supplement or placebo (alanine) twice daily for one week before and two weeks after lumbar spine surgery * Record pain levels and medication use in a diary * Perform functional assessments at routine follow-up visits after surgery * Undergo blood draws to monitor nutrition status and health * Undergo one spine magnetic resonance imaging (MRI) before surgery as part of routine surgical planning * Undergo one additional spine MRI after surgery to monitor PMV after treatment
Researchers will compare the group that consumed EAA supplement and the group that consumed placebo to see if there is a difference in paraspinal muscle volume changes and measures of spinal alignment, functional abilities, pain levels, and opioid use.
The 2 groups in the trial
- TreatmentTreatment being tested
One scoop (20 grams) of EAAs mixed in 10-12 ounces of a cold beverage to taste preference consumed orally twice daily between meals for 1 week before surgery up until 2 weeks after surgery. Active ingredients: L-leucine (3.6g), L-lysine as L-lysine HCl (3.2g), L-phenylalanine (3.2g), L-valine (2.4g), L-threonine (2.8g), L-isoleucine (2.0g), L-methionine (0.6g), and L-histidine as L-histidine HCl (2.2g)
Treatment: Essential amino acids
- PlaceboPlacebo, for comparison
One scoop (20 grams) of placebo mixed in 10-12 ounces of a cold beverage to taste preference consumed orally twice daily between meals for 1 week before surgery up until 2 weeks after surgery. Active ingredients: alanine
Treatment: Alanine
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Effects of a Targeted Nutritional Supplement on Muscle Volume and Function After Posterior Lumbar Spine Surgery: A Randomized, Placebo-Controlled, Double-Blind Clinical Trial
- Record updated
- 29 May 2025